The ICH topics are divided into four categories and ICH topic codes are assigned according to these categories.
Harmonisation achievements in the Quality area include
pivotal milestones such as the conduct of stability studies, defining
relevant thresholds for impurities testing and a more flexible approach
to pharmaceutical quality based on Good Manufacturing Practice (GMP)
risk management.
ICH has produced a comprehensive set of safety Guidelines
to uncover potential risks like carcinogenicity, genotoxicity and
reprotoxicity. A recent breakthrough has been a non-clinical testing
strategy for assessing the QT interval prolongation liability: the
single most important cause of drug withdrawals in recent years.
The work carried out by ICH under the Efficacy heading is
concerned with the design, conduct, safety and reporting of clinical
trials. It also covers novel types of medicines derived from
biotechnological processes and the use of pharmacogenetics/genomics
techniques to produce better targeted medicines.
Those are the cross-cutting topics which do not fit
uniquely into one of the Quality, Safety and Efficacy categories. It
includes the ICH medical terminology (MedDRA), the Common Technical
Document (CTD) and the development of Electronic Standards for the
Transfer of Regulatory Information (ESTRI).
Posted in: ICH
Email This
BlogThis!
Share to Facebook
0 comments:
Post a Comment